On this page
How do you prepare an NDA or ANDA ownership transfer?
Reconcile the former owner’s transfer-of-rights document with the new owner’s signed application form, commitments, effective date and application-record statement or FDA copy request under section 314.72. Confirm the ANDA link through section 314.99. For a BLA, establish the responsible center and licensing process before reusing a marketing-application transfer template.
Before you begin
FDA human-drug marketing application ownership changes and biologic license reissuance. Center, pathway and approved/pending status must be established.
What you will prepare: A pathway-specific transfer packet with commitments and records reconciled between both parties.
For NDAs and ANDAs, reconcile both sides of §314.72
At transfer, the former owner supplies a document stating that all rights to the application transferred. The new owner supplies a signed application form and a document committing to the prior owner’s agreements, promises and conditions, giving the effective date, and addressing possession of a complete approved application and required records or requesting a copy from FDA. Section 314.99 makes the ownership provisions applicable to ANDAs.
Create separate evidence rows for each commitment and record category. A transaction agreement is not evidence that every regulatory record was delivered. Identify pending supplements and obligations with continuing deadlines. Changes to approved conditions require their own reporting assessment under §314.72(b) and the applicable change rules.
For biologics, use the licensing process for the responsible center
CBER SOPP 8403 §V describes applicant/product ownership changes as administrative actions through product correspondence and coordinates relevant revocation and issuance when products move between applicants. Its reissuance discussion calls for the new applicant’s name and information about changes in personnel, manufacturing, procedures and facilities. It is CBER staff policy; establish the appropriate CDER process for a CDER-regulated BLA rather than labeling the SOPP a universal BLA regulation.
Reconcile the name intended for the license with Form 356h. Do not interpret a request for reissuance as issued permission to manufacture or distribute under the new arrangement. Obtain the actual agency licensing action and have the regulatory owner establish which changes need additional submissions.
Worked check: ownership transfer includes a manufacturing change
Fictional exercise: an NDA buyer intends to manufacture at a new site on the closing date. The ownership packet can identify the transaction, but it does not establish that the new site is approved or otherwise permitted for use. Separate the ownership effective date from the authorized implementation of manufacturing changes.
If the application is instead a CBER BLA, replace the NDA transfer analysis with the licensing and product-correspondence process. If the team cannot identify the responsible center, the filing route remains undetermined. Preserve draft factual inputs while resolving that boundary.
Review the two parties’ packet against the continuing application
For an NDA or ANDA, prepare a paired review sheet. It should show both what each party states and the evidence supporting that statement.
| Review row | Former-owner input | Receiving-owner check |
|---|---|---|
| Regulatory asset | Exact application and transfer of its rights | Same application identified on the signed form |
| Effective date | Transaction evidence supporting the handoff | Date reconciles with the receiving document |
| Continuing commitments | Agreements, promises, conditions and open actions | Named owners can explain the next action and due date |
| Application records | Delivered application, supplements and required records | Completeness assessed or FDA copy request addressed |
| Other changes | Manufacturing, labeling or facility changes identified | Separate reporting and implementation decisions recorded |
Records exercise: the new owner receives the approved application but discovers that a pending supplement and its latest FDA correspondence are absent. Keep the possession statement accurate, identify the missing material, and assign its recovery. Reconcile open regulatory work even when it is outside the particular approved-copy statement. Do not turn a purchase agreement into evidence that every document is already available.
Section 314.72(b) contains a specific annual-report provision for a label or labeling change to the brand or manufacturer, packer or distributor name. Check the actual change against that provision; it does not make every labeling or manufacturing change an annual-report matter.
For a CBER BLA, replace the NDA/ANDA sheet with the applicable SOPP 8403 product-correspondence and licensing review. Establish the products and parties, coordinated submissions and resulting agency action. Keep changes beyond the administrative transaction separately assessed. A license request and an issued licensing action represent different states.
Reconcile identities with Form 356h, then use the cover-letter guide to point to the actual packet. Use the contact-change guide for associated communication updates.
Your preparation checklist
0/3 checkedUse this to track your review in this visit. Checks are not saved and do not establish regulatory compliance.
Frequently asked questions
Must the former and new NDA owners both submit transfer information?
Yes. Section 314.72 assigns different information to each party at transfer. The former owner addresses the transfer of application rights; the new owner supplies its signed application form and the required commitments, effective date and records statement or request. One party’s letter does not replace the other’s responsibilities.
What if the new owner does not have the complete approved application?
Section 314.72 provides for a request for a copy from FDA as an alternative to the specified possession statement. Describe the actual records position accurately and address that route with the regulatory owner. Do not sign a complete-copy statement merely because the commercial transaction has closed.
Does transferring ownership authorize a new manufacturing site immediately?
No. The ownership transaction and changes to approved application conditions need separate assessment. Establish the applicable reporting and implementation requirements for the site change. A closing date, new owner’s signature or licensing request does not establish that the new manufacturing arrangement may be used.
Is section 601.9 the routine corporate name-change procedure for every BLA?
No. Section 601.9 addresses reissuance or reinstatement associated with suspended or revoked licenses and noncomplying locations or products. For CBER administrative applicant or ownership changes, review SOPP 8403 and the actual licensing process. Establish the responsible center instead of treating either source as a universal BLA transfer template.
Sources and revisions
Requirements, source recommendations and editorial preparation advice have different roles. Review the scope and revision of the source you use.
Regulation
21 CFR Part 314: drug marketing applications ↗Current part reopened September 22, 2026; §§314.50, 314.53, 314.65, 314.72, 314.94, 314.99, 314.108 and 314.150–162 inspected. Not a general BLA rule.
FDA resource
CBER SOPP 8403: issuance, reissuance and voluntary revocation ↗Version 6, effective February 27, 2023; §V.C–G. CBER staff procedure, not an independent applicant regulation. PDF reopened September 22, 2026.
Regulation
21 CFR Part 601: biologics licensing ↗Current part reopened September 22, 2026; §§601.5 and 601.9 distinguish revocation and reissuance.
Technical specification · placement only
FDA eCTD v4.0 comprehensive hierarchy ↗Version 2.2, February 2025. Section 1.3.1.5. A heading identifies placement, not mandatory applicability.